Abstract 70P
Background
The efficacy and safety of the three-drug combination of eribulin (E), trastuzumab (T), and pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) as first-line treatment was reported. The overall response rate (complete response [CR] + partial response [PR]) was 80.0% (95% confidence interval [CI], 59.3–93.2%), and the clinical benefit rate (CR + PR + stable disease ≥24 weeks; CBR) was 84.0% (95% CI, 63.9–95.5%). Median time to treatment failure with E was 9.1 months (95% CI, 4.3–13.9 months), and median progression-free survival was 23.1 months (95% CI, 14.4–31.8 months). The most common treatment-emergent adverse events (TEAEs) were alopecia (92.0%), fatigue (68.0%), and sensory peripheral neuropathy (60.0%). Grade 3/4 TEAEs occurred in 11 patients (44.0%). The only grade 4 TEAE was neutrophil count decreased (16.0%). Neither grade 4 peripheral neuropathy nor febrile neutropenia occurred (Inoue K et al Investigational New Drugs 2019; 180:135–46). We report the overall survival results and the efficacy of post-ETP treatments at 5.5 years after the last enrollment.
Methods
E 1.4 mg/m2 (days 1 and 8), T 8 mg/kg over 90 min and 6 mg/kg over 30 min, and P 840 mg/body over 60 min and 420 mg/body over 30 min were administered intravenously in 21-day cycles.
Results
From April 2016 to November 2017, 25 women received ETP therapy and 12 of the 25 survived with a median OS of 78.4 months, 95% CI 26.4-NA months. Subset analysis by log-rank test showed a significant difference (P=0.0114) and hazard ratio; 3.063 95% CI 1.002-9.361 in hemoglobulin (≥12 vs. ≤12 mg/dl), but not in estrogen receptor status and neutrophil/lymphocyte ratio (≥2 vs. <2). T-emtansine, capecitabine + TP, T-deruxtecan, and epirubicin + cyclophosphamide were administered after ETP with CBR of 72.2% (13/18 patients), 80.0% (4/5 patients), 66.7% (2/3 patients) and 33.3% (1/3 patients), respectively.
Conclusions
ETP therapy showed acceptable efficacy and overall survival as first-line therapy for patients with HER2-positive Japanese MBC.
Clinical trial identification
UMIN000021585.
Editorial acknowledgement
Legal entity responsible for the study
Saitama breast cancer clinical study group.
Funding
Has not received any funding.
Disclosure
K. Inoue: Financial Interests, Institutional, Funding: AstraZeneca, Chugai Pharma, Daiichi Sankyo, Eisai, Eli Lilly, Kyowa-Kirin, MSD, Novartis, Pfizer, Taiho, Ono, Astellas, Sanofi. All other authors have declared no conflicts of interest.
Resources from the same session
16P - Patient and healthcare practitioner preferences in early-stage triple-negative breast cancer treatment: A discrete choice experiment
Presenter: Jiun-I Lai
Session: Poster Display
Resources:
Abstract
17P - Initial outcomes of the ACT Now PRIME CARE for breast cancer: Prevention of Breast canceR (screening/ stage shifting) utilizing Integrated MobilE Clinics and pAtient Reported online Evaluations and Education
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
18P - Optimizing premenopausal HR+ HER2–ve eBC management in India: Insights from expert consensus
Presenter: Anitha Ramesh
Session: Poster Display
Resources:
Abstract
19P - Referral patterns among breast cancer patients in county-level hospitals in China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
20P - Real-world treatment of HER2+ and HR+/HER2- early breast cancer in county areas of China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
21P - Duration of breast cancer trials: Analysis of predicted versus actual completion date
Presenter: Daniëlle Verschoor
Session: Poster Display
Resources:
Abstract
22P - Impact of an online Asian genetic risk calculator on risk perception: Cancer-related distress and uptake of genetic counselling among Malaysian breast cancer patients (The ARiCa Study)
Presenter: HEAMANTHAA Padmanabhan
Session: Poster Display
Resources:
Abstract
23P - Consensus statements and expert recommendations for BRCAm breast cancer in the Asia-Pacific region (STREAM-AP)
Presenter: Soo Chin Lee
Session: Poster Display
Resources:
Abstract
24P - Germline genetic testing for hereditary cancer: A retrospective analysis in a single site referral centre in Malaysia
Presenter: Vivian Lee
Session: Poster Display
Resources:
Abstract
25P - Clinical presentations and prognostication of HER2-low breast cancer in Taiwan
Presenter: Bo-Fang Chen
Session: Poster Display
Resources:
Abstract